Recent studies have shown that CAR-T cells targeting CD70 have displayed remarkable efficacy in combating a variety of tumors, including renal cell carcinoma, acute myeloid leukemia, glioblastoma, gliomas, head and neck squamous cell carcinoma, CD19-negative B-cell lymphoma, and melanoma, both in animal models and pre-clinical study [20–28]. This evidence concerns the gene CD70 and renal cell carcinoma.